Condition 1: Crohn's disease. Condition 2: Ulcerative colitis. Crohn's disease [regional enteritis] Ulcerative colitis
Conditions
Interventions
Intervention 1: Intervention group: Standard treatment (Mesalazine tablet 1000 mg 3 times a day, Kimidaro Pharmaceutical Company) plus crocin capsule 15 mg (Darumed Pharmaceutical Company) twice a day
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inflammatory bowel diseases including Crohn's or ulcerative colitis Informed consent to participate in the study No history of other autoimmune diseases No history of underlying diseases No use of other medicinal plants Patients with moderate type Inflammatory bowel diseases Insensitivity to salicylates Insensitivity to any of the saffron compounds
Exclusion criteria
Exclusion criteria: Reluctance to continue participating in the study Death of the patient Pregnancy or breastfeeding In case of any unwanted side effects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The score of clinical symptoms of colitis in the Partial Mayo score questionnaire. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Partial Mayo score questionnaire.;The score of the clinical symptoms of Crohn in the Harvey Bradshaw index questionnaire. Timepoint: Before the start of the intervention and 8 weeks after the start of the intervention. Method of measurement: Harvey Bradshaw index questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhorbanali Rahimian
Shahre-kord University of Medical Sciences
Outcome results
None listed